Dr Reddy’s Laboratories has partnered with Japan’s Takeda Pharmaceuticals to promote and distribute Qdenga, the dengue vaccine, in India. Neetu Chandra Sharma, Business Today, explains why the partnership is strategically important, how it fits Dr Reddy’s existing vaccine portfolio and what it means for India’s emerging preventive healthcare market. The discussion covers Qdenga’s two-dose schedule, awareness, access, affordability and the role of doctors and healthcare institutions.
Gold prices: Weak dollar, central bank buying may trigger next big move, says Vandana Bharti
Responsive Ind shares drop 5% as board shelves buyback proposal
FMCG Vs Pharma Stocks: Which Sector Has Better Growth Potential?
100% Tariff Threat: Why Trump’s Russia Bill Puts India, China In Focus
Anthropic’s AI security tool hacked OpenAI systems and accessed employee credentials: Here’s what happenedGold prices: Weak dollar, central bank buying may trigger next big move, says Vandana BhartiResponsive Ind shares drop 5% as board shelves buyback proposal
Avalon Technologies shares hit record high on MOFSL estimates 
Cupid, Avalon, Pine Labs, ACME Solar, Groww, Belrise: FTSE rebalancing, inflow preview
Vedanta share price jumps as board okays up to Rs 3,500 crore worth NCDsFMCG Vs Pharma Stocks: Which Sector Has Better Growth Potential?100% Tariff Threat: Why Trump’s Russia Bill Puts India, China In Focus
Tata Sons Succession Battle: Noel Tata, Tata Trusts & Shapoorji Pallonji Stake Sale Explained
Tata Group Crisis: Stocks Fall As Leadership Uncertainty Rattles Investors
Canada Gets EU ‘Associate Member’ Offer As Carney Seeks Deeper Ties Beyond U.S.
